Logo image of CGON

CG ONCOLOGY INC (CGON) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CGON - US1569441009 - Common Stock

52.58 USD
-1.14 (-2.12%)
Last: 1/13/2026, 8:00:00 PM
52.16 USD
-0.42 (-0.8%)
After Hours: 1/13/2026, 8:00:00 PM
Fundamental Rating

3

Taking everything into account, CGON scores 3 out of 10 in our fundamental rating. CGON was compared to 528 industry peers in the Biotechnology industry. While CGON seems to be doing ok healthwise, there are quite some concerns on its profitability. CGON is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CGON has reported negative net income.
CGON had a negative operating cash flow in the past year.
CGON Yearly Net Income VS EBIT VS OCF VS FCFCGON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

CGON has a Return On Assets of -20.75%. This is in the better half of the industry: CGON outperforms 75.57% of its industry peers.
With an excellent Return On Equity value of -22.03%, CGON belongs to the best of the industry, outperforming 82.20% of the companies in the same industry.
Industry RankSector Rank
ROA -20.75%
ROE -22.03%
ROIC N/A
ROA(3y)-25.11%
ROA(5y)N/A
ROE(3y)-27.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CGON Yearly ROA, ROE, ROICCGON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

CGON does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGON Yearly Profit, Operating, Gross MarginsCGON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -10K -20K -30K

More info and screens

6

2. Health

2.1 Basic Checks

CGON does not have a ROIC to compare to the WACC, probably because it is not profitable.
CGON has more shares outstanding than it did 1 year ago.
There is no outstanding debt for CGON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CGON Yearly Shares OutstandingCGON Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
CGON Yearly Total Debt VS Total AssetsCGON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

CGON has an Altman-Z score of 61.15. This indicates that CGON is financially healthy and has little risk of bankruptcy at the moment.
CGON has a better Altman-Z score (61.15) than 97.16% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that CGON is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, CGON is in line with its industry, outperforming 47.73% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 61.15
ROIC/WACCN/A
WACC8.83%
CGON Yearly LT Debt VS Equity VS FCFCGON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 22.79 indicates that CGON has no problem at all paying its short term obligations.
With an excellent Current ratio value of 22.79, CGON belongs to the best of the industry, outperforming 96.59% of the companies in the same industry.
CGON has a Quick Ratio of 22.74. This indicates that CGON is financially healthy and has no problem in meeting its short term obligations.
CGON has a Quick ratio of 22.74. This is amongst the best in the industry. CGON outperforms 96.59% of its industry peers.
Industry RankSector Rank
Current Ratio 22.79
Quick Ratio 22.74
CGON Yearly Current Assets VS Current LiabilitesCGON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

CGON shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.58%, which is quite impressive.
The Revenue has grown by 217.84% in the past year. This is a very strong growth!
CGON shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -52.09% yearly.
EPS 1Y (TTM)61.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
Revenue 1Y (TTM)217.84%
Revenue growth 3Y-52.09%
Revenue growth 5YN/A
Sales Q2Q%3774.42%

3.2 Future

CGON is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.81% yearly.
Based on estimates for the next years, CGON will show a very strong growth in Revenue. The Revenue will grow by 280.24% on average per year.
EPS Next Y-56.59%
EPS Next 2Y-37.21%
EPS Next 3Y-19.32%
EPS Next 5Y31.81%
Revenue Next Year79.3%
Revenue Next 2Y478.49%
Revenue Next 3Y382.5%
Revenue Next 5Y280.24%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CGON Yearly Revenue VS EstimatesCGON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
CGON Yearly EPS VS EstimatesCGON Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CGON. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGON. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGON Price Earnings VS Forward Price EarningsCGON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGON Per share dataCGON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

CGON's earnings are expected to decrease with -19.32% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-37.21%
EPS Next 3Y-19.32%

More info and screens

0

5. Dividend

5.1 Amount

CGON does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CG ONCOLOGY INC

NASDAQ:CGON (1/13/2026, 8:00:00 PM)

After market: 52.16 -0.42 (-0.8%)

52.58

-1.14 (-2.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-26 2026-03-26/bmo
Inst Owners103.59%
Inst Owner Change0.01%
Ins Owners0.66%
Ins Owner Change0%
Market Cap4.24B
Revenue(TTM)2.17M
Net Income(TTM)-151.48M
Analysts83.81
Price Target72.97 (38.78%)
Short Float %17.93%
Short Ratio15.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.55%
Min EPS beat(2)-15.32%
Max EPS beat(2)0.21%
EPS beat(4)1
Avg EPS beat(4)-14.42%
Min EPS beat(4)-33.19%
Max EPS beat(4)0.21%
EPS beat(8)3
Avg EPS beat(8)-71%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1150.64%
Min Revenue beat(2)-100%
Max Revenue beat(2)2401.28%
Revenue beat(4)2
Avg Revenue beat(4)680.33%
Min Revenue beat(4)-100%
Max Revenue beat(4)2401.28%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.18%
PT rev (3m)10.57%
EPS NQ rev (1m)-1.68%
EPS NQ rev (3m)-4.42%
EPS NY rev (1m)-0.88%
EPS NY rev (3m)-1.3%
Revenue NQ rev (1m)-16.23%
Revenue NQ rev (3m)-24.38%
Revenue NY rev (1m)-2.01%
Revenue NY rev (3m)623.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1951.07
P/FCF N/A
P/OCF N/A
P/B 6.17
P/tB 6.3
EV/EBITDA N/A
EPS(TTM)-2.04
EYN/A
EPS(NY)-2.67
Fwd EYN/A
FCF(TTM)-1.45
FCFYN/A
OCF(TTM)-1.45
OCFYN/A
SpS0.03
BVpS8.52
TBVpS8.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.75%
ROE -22.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.11%
ROA(5y)N/A
ROE(3y)-27.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.38%
Cap/Sales 15.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.79
Quick Ratio 22.74
Altman-Z 61.15
F-Score3
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
EPS Next Y-56.59%
EPS Next 2Y-37.21%
EPS Next 3Y-19.32%
EPS Next 5Y31.81%
Revenue 1Y (TTM)217.84%
Revenue growth 3Y-52.09%
Revenue growth 5YN/A
Sales Q2Q%3774.42%
Revenue Next Year79.3%
Revenue Next 2Y478.49%
Revenue Next 3Y382.5%
Revenue Next 5Y280.24%
EBIT growth 1Y-88.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-82.96%
EBIT Next 3Y-32.29%
EBIT Next 5YN/A
FCF growth 1Y-221.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-220.44%
OCF growth 3YN/A
OCF growth 5YN/A

CG ONCOLOGY INC / CGON FAQ

Can you provide the ChartMill fundamental rating for CG ONCOLOGY INC?

ChartMill assigns a fundamental rating of 3 / 10 to CGON.


Can you provide the valuation status for CG ONCOLOGY INC?

ChartMill assigns a valuation rating of 0 / 10 to CG ONCOLOGY INC (CGON). This can be considered as Overvalued.


What is the profitability of CGON stock?

CG ONCOLOGY INC (CGON) has a profitability rating of 1 / 10.


Can you provide the financial health for CGON stock?

The financial health rating of CG ONCOLOGY INC (CGON) is 6 / 10.